Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada





Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company,

announced that it has entered into an exclusive License Agreement with

Knight......
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Friday, 11 January
Share |